Total Payments
$3,109
2024 Payments
$14.66
Companies
19
Transactions
203
Medicare Patients
4,870
Medicare Billing
$390,151
Payment Breakdown by Category
Food & Beverage$3,103 (99.8%)
Education$6.02 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,103 | 202 | 99.8% |
| Education | $6.02 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,045 | 70 | $0 (2022) |
| Lilly USA, LLC | $379.16 | 30 | $0 (2022) |
| PFIZER INC. | $365.77 | 25 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $324.94 | 17 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $253.04 | 15 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $169.57 | 12 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $142.82 | 7 | $0 (2021) |
| Amarin Pharma Inc. | $83.04 | 5 | $0 (2020) |
| Amgen Inc. | $71.31 | 5 | $0 (2021) |
| Eisai Inc. | $56.54 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14.66 | 1 | Kowa Pharmaceuticals America, Inc. ($14.66) |
| 2022 | $87.31 | 5 | Novo Nordisk Inc ($55.52) |
| 2021 | $294.95 | 17 | Novo Nordisk Inc ($123.23) |
| 2020 | $736.77 | 45 | Novo Nordisk Inc ($193.31) |
| 2019 | $518.91 | 42 | Novo Nordisk Inc ($176.74) |
| 2018 | $440.99 | 30 | Novo Nordisk Inc ($171.94) |
| 2017 | $1,015 | 63 | Novo Nordisk Inc ($324.22) |
All Payment Transactions
203 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/08/2024 | Kowa Pharmaceuticals America, Inc. | ZORYVE (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: DERMATOLOGY | ||||||
| 10/13/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: Respiratory | ||||||
| 07/14/2022 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: Diabetes | ||||||
| 07/13/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: Diabetes | ||||||
| 06/08/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Diabetes | ||||||
| 05/11/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: Diabetes | ||||||
| 08/17/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $8.78 | General |
| Category: Diabetes | ||||||
| 08/09/2021 | Lilly USA, LLC | TRULICITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: Diabetes | ||||||
| 08/02/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Diabetes | ||||||
| 07/14/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $12.54 | General |
| Category: Diabetes | ||||||
| 06/28/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Diabetes | ||||||
| 06/22/2021 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Inflammation | ||||||
| 06/08/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Diabetes | ||||||
| 05/24/2021 | Lilly USA, LLC | TRULICITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: Diabetes | ||||||
| 05/06/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/19/2021 | Lilly USA, LLC | TRULICITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Diabetes | ||||||
| 04/08/2021 | Merck Sharp & Dohme Corporation | BELSOMRA (Drug), JANUVIA, JANUMET | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: NEUROSCIENCE | ||||||
| 04/01/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/11/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: Diabetes | ||||||
| 02/11/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/09/2021 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Bone Health | ||||||
| 02/04/2021 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/26/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: Diabetes | ||||||
| 12/11/2020 | Eisai Inc. | Dayvigo (Drug) | Food and Beverage | Cash or cash equivalent | $16.55 | General |
| Category: Neurology | ||||||
| 11/19/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 928 | 1,574 | $159,020 | $86,711 |
| 2022 | 17 | 1,146 | 1,944 | $173,130 | $92,958 |
| 2021 | 19 | 1,318 | 2,129 | $193,495 | $104,022 |
| 2020 | 19 | 1,478 | 2,580 | $236,465 | $106,461 |
Total Patients
4,870
Total Services
8,227
Medicare Billing
$390,151
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 253 | 619 | $92,850 | $50,169 | 54.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 172 | 346 | $34,600 | $20,468 | 59.2% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 87 | 87 | $3,045 | $2,914 | 95.7% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 12 | 14 | $4,200 | $2,560 | 61.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 23 | $5,520 | $2,525 | 45.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 86 | 87 | $2,175 | $2,132 | 98.0% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 36 | 40 | $3,000 | $1,977 | 65.9% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 22 | 27 | $2,295 | $1,015 | 44.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 16 | 18 | $1,530 | $751.72 | 49.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 18 | 20 | $1,400 | $701.59 | 50.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 48 | $1,200 | $464.48 | 38.7% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 27 | 29 | $580.00 | $266.56 | 46.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 44 | 50 | $750.00 | $250.92 | 33.5% |
| 93005 | Routine electrocardiogram (ecg) using at least 12 leads with tracing | Office | 2023 | 44 | 50 | $3,750 | $180.40 | 4.8% |
| 81003 | Automated urinalysis test | Office | 2023 | 37 | 69 | $690.00 | $151.80 | 22.0% |
| 82947 | Blood glucose (sugar) level | Office | 2023 | 30 | 34 | $850.00 | $127.05 | 14.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 11 | 13 | $585.00 | $57.60 | 9.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 266 | 616 | $92,400 | $49,681 | 53.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 173 | 401 | $40,100 | $23,730 | 59.2% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2022 | 121 | 123 | $4,305 | $3,854 | 89.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 30 | $7,200 | $3,175 | 44.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 126 | 128 | $3,200 | $3,113 | 97.3% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2022 | 12 | 13 | $3,900 | $2,468 | 63.3% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2022 | 45 | 53 | $3,975 | $1,591 | 40.0% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 90 | 156 | $3,120 | $1,477 | 47.4% |
About Dr. William King, MD
Dr. William King, MD is a Internal Medicine healthcare provider based in Eufaula, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891715892.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William King, MD has received a total of $3,109 in payments from pharmaceutical and medical device companies, with $14.66 received in 2024. These payments were reported across 203 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($3,103).
As a Medicare-enrolled provider, King has provided services to 4,870 Medicare beneficiaries, totaling 8,227 services with total Medicare billing of $390,151. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Eufaula, AL
- Active Since 07/20/2006
- Last Updated 02/09/2010
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1891715892
Products in Payments
- Ozempic (Drug) $574.13
- TRULICITY (Drug) $295.39
- Victoza (Drug) $271.45
- ELIQUIS (Drug) $260.76
- INVOKANA (Drug) $210.90
- FARXIGA (Drug) $149.94
- ENTRESTO (Drug) $142.82
- JANUVIA (Drug) $138.70
- XARELTO (Drug) $108.02
- CHANTIX (Drug) $84.17
- Vascepa (Drug) $83.04
- Saxenda (Drug) $81.17
- SYMBICORT (Drug) $74.24
- Dayvigo (Drug) $56.54
- Rybelsus (Drug) $55.52
- JARDIANCE (Drug) $49.39
- Tresiba (Drug) $40.20
- EVENITY (Biological) $27.57
- TRELEGY ELLIPTA (Drug) $24.76
- Levemir (Drug) $22.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.